References
- Dhar SK, K V, Damodar S, Gujar S, Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 2021;7(2):e06155.
- Worldometer. Coronavirus statistics. Available from: https://www.worldometers.info/coronavirus/ [Accessed 31 August 2022]
- Sabaka P, Koščálová A, Straka I, et al. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. BMC Infect Dis. 2021;21(1):308.
- Santa Cruz A, Mendes-Frias A, Oliveira AI, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Front Immunol. 2021;12.613422.
- Oi Y, Ogawa F, Yamashiro T, et al. Prediction of prognosis in patients with severe COVID-19 pneumonia using CT score by emergency physicians: a single-center retrospective study. Sci Rep. 2023;13(1):4045.
- Pons MJ, Ymaña B, Mayanga-Herrera A, Sáenz Y, Alvarez-Erviti L, Tapia-Rojas S, et al. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort. Front Immunol. 2021;12:700921.
- Lu L, Zhang H, Dauphars DJ, He YW. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. Trends in Immunology. 2021;42:3–5.
- Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022;19(1):92.
- Basheer M, Saad E, Assy N. The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. COVID. 2022;2(5):540–52.
- Bonnet B, Cosme J, Dupuis C, et al. Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation. EBioMedicine. 2021;73:103622.
- Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020;5(49).eabd7114.
- Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell. 2020;182(6):1419–40.
- Li J, Rong L, Cui R, et al. Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19. Ann Palliat Med. 2021;10(4):3706–14.
- Pons MJ, Ymaña B, Mayanga-Herrera A, et al. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort. Front Immunol. 2021;12:700921.
- del Valle-Mendoza J, Tarazona-Castro Y, Merino-Luna A, et al. Comparison of cytokines levels among COVID-19 patients living at sea level and high altitude. BMC Infect Dis. 2022;22:96.
- Ramasamy S, Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clin Microbiol Rev. 2021;34(3):e00299–20.
- Shekhawat J, Gauba K, Gupta S, et al. Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm. Indian J Clin Biochem. 2021;36(4):440–50.
- Mazaheri T, Ranasinghe R, Al-Hasani W, et al. A cytokine panel and procalcitonin in COVID-19, a comparison between intensive care and non-intensive care patients. PLoS One. 2022;17(5):e0266652.
- Lampart M, Zellweger N, Bassetti S, et al. Clinical utility of inflammatory biomarkers in COVID-19 in direct comparison to other respiratory infections—A prospective cohort study. PLoS One. 2022;17(5):e0269005.
- Rahayu R, Winarto W, Nasihun T. Interleukin-6 and C-reactive Protein on Admission as Predictor of Mortality in Severe COVID-19 Patients: A Retrospective Cohort Study. Open Access Maced J Med Sci. 2022;10(B):227–31.
- Brennan K, Zheng J. Interleukin 8. In Enna SJ, Bylund DB (eds): xPharm: The Comprehensive Pharmacology Reference. Amsterdam: Elsevier. 2007, p. 1–4.
- Li L, Li J, Gao M, et al. Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients. Front Immunol. 2021;11:602395.
- Cesta MC, Zippoli M, Marsiglia C, et al. The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome. Front Pharmacol. 2022;12:808797.
- Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652.
- Islam H, Chamberlain TC, Mui AL, Little JP. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action? Front Immunol. 2021;12:677008.
- Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827.
- Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology. 2022;30(3):789–98.
- Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123–30.
- Nagant C, Ponthieux F, Smet J, et al. A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. Int J Infect Dis. 2020;101:342–5.
- Gotluru C, Roach A, Cherry SH, Runowicz CD. Sex, Hormones, Immune Functions, and Susceptibility to Coronavirus Disease 2019 (COVID-19)-Related Morbidity. Obstet Gynecol. 2021;137(3):423–9.
- Bigdelou B, Sepand MR, Najafikhoshnoo S, et al. COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes. Front Immunol. 2022;13:890517.
- Qin L, Li X, Shi J, et al. Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan. J Med Virol. 2020;92(11):2684–92.
- Queiroz MAF, Neves PFM das, Lima SS, et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front Cell Infect Microbiol. 2022;12:922422.
- Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front Physiol. 2021;11:571416.
- Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obesity Reviews. 2015;16(12):1017–29.
- Kim J, Bajaj M. Normal Adipose Tissue Biology: Adipocytokines and Inflammation. In McManus LM, Mitchell R (eds): Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Amsterdam: Elsevier. 2014, p. 488–97.
- Guo J, Wang S, Xia H, et al. Cytokine Signature Associated With Disease Severity in COVID-19. Front Immunol. 2021;12:681516.
- Liu QQ, Cheng A, Wang Y, et al. Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study. BMJ Open. 2020;10(11):e041471.
- Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–24.
- Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446.
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.
- Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: Implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67(11):3037–46.
- Isabel García-Laorden M, Lorente JA, Flores C, Slutsky AS, Villar J. Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise. Ann Transl Med. 2017;5(14):283.
- Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517–20.
- Zhou J, He W, Liang J, et al. Association of Interleukin-6 Levels with Morbidity and Mortality in Patients with Coronavirus Disease 2019 (COVID-19). Jpn J Infect Dis 2021;74(4):293–8.